News & Events about Neuropace Inc.
MOUNTAIN VIEW, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter and full year of 2022 after ...
NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced that the first patient with Lennox-Gastaut Syndrome (LGS) was treated in its feasibility investigational device exemption (IDE) study. LGS is a...
MOUNTAIN VIEW, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will be participating in the upcoming 2022 RBC Capital Markets Global Healthcare ...
NeuroPace (NASDAQ:NPCE Get Rating) released its quarterly earnings data on Thursday. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.11), MarketWatch Earnings reports. NeuroPace updated its Q1 2022 guidance to EPS and its FY 2022 ...
NeuroPace, Inc. (NASDAQ:NPCE) has been given a consensus recommendation of Buy by the six ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The ...